Literature DB >> 15329364

Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.

Anjali Sharma1, Sadhna Sharma, G K Khuller.   

Abstract

OBJECTIVES: This study was carried out to explore lectin-functionalized poly (lactide-co-glycolide) nanoparticles (PLG-NPs) as bioadhesive drug carriers against tuberculosis (TB), in order to reduce the drug dosage frequency of antitubercular drugs and thus improve patient compliance in TB chemotherapy.
METHODS: Wheat germ agglutinin (WGA)-coated PLG-NPs were prepared by a two-step carbodiimide procedure. This formulation was administered to guinea pigs through the oral/aerosol route for a detailed pharmacokinetic and chemotherapeutic evaluation. Immunological or hepatotoxic effects of WGA lectin, if any, were also determined.
RESULTS: WGA-functionalized PLG-NPs were in the size range of 350-400 nm, with binding of 3-3.5 microg of WGA/mg of PLG-NPs and drug encapsulation efficiency of 54%-66%. Upon administration of lectin-coated PLG-NPs through the oral/aerosol route, the presence of drugs in plasma was observed for 6-7 days for rifampicin and 13-14 days for isoniazid and pyrazinamide. However, upon administration of uncoated PLG-NPs (oral/aerosolized) rifampicin was detectable in plasma for 4-6 days, whereas isoniazid and pyrazinamide were detectable for 8-9 days. All three drugs were present in lungs, liver and spleen for 15 days. Administration of WGA-coated PLG-NPs caused a significant (P < 0.001) increase in the relative bioavailability of antitubercular drugs. Chemotherapeutic studies revealed that three doses of oral/nebulized lectin-coated nanoparticles fortnightly could yield undetectable mycobacterial colony forming units (cfu); this was achievable with 45 doses of oral free drugs.
CONCLUSION: WGA-functionalized PLG-NPs could be potential drug carriers for antitubercular drugs through the oral as well as aerosol route for effective TB control.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15329364     DOI: 10.1093/jac/dkh411

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  36 in total

Review 1.  Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?

Authors:  Roudayna Diab; Chiraz Jaafar-Maalej; Hatem Fessi; Philippe Maincent
Journal:  AAPS J       Date:  2012-07-06       Impact factor: 4.009

Review 2.  The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.

Authors:  Svetlana Gelperina; Kevin Kisich; Michael D Iseman; Leonid Heifets
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

Review 3.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

Review 4.  Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.

Authors:  Young H Lim; Kristin M Tiemann; David A Hunstad; Mahmoud Elsabahy; Karen L Wooley
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-03-25

5.  Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.

Authors:  Takuto Mizoe; Tetsuya Ozeki; Hiroaki Okada
Journal:  AAPS PharmSciTech       Date:  2008-06-18       Impact factor: 3.246

6.  Advances in biomimetic regeneration of elastic matrix structures.

Authors:  Balakrishnan Sivaraman; Chris A Bashur; Anand Ramamurthi
Journal:  Drug Deliv Transl Res       Date:  2012-10       Impact factor: 4.617

7.  Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.

Authors:  Jean C Sung; Danielle J Padilla; Lucila Garcia-Contreras; Jarod L Verberkmoes; David Durbin; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Pharm Res       Date:  2009-04-30       Impact factor: 4.200

8.  Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles.

Authors:  Manoj Nahar; Narendra K Jain
Journal:  Pharm Res       Date:  2009-10-20       Impact factor: 4.200

Review 9.  Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.

Authors:  Roshni Iyer; Connie C W Hsia; Kytai T Nguyen
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

10.  Quantification of particle-conjugated or particle-encapsulated peptides on interfering reagent backgrounds.

Authors:  Woon Teck Yap; W Kelsey Song; Niharika Chauhan; P Nina Scalise; Radhika Agarwal; Stephen D Miller; Lonnie D Shea
Journal:  Biotechniques       Date:  2014-07-01       Impact factor: 1.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.